Story
Analysis Identifies Five US Banks With Highest Modeled Upside

Summary
A recent analysis identified five U.S. banking stocks, including Atlanticus Holdings and Inter & Co, with the highest modeled valuation upside. However, the report cautions that individual balance sheet risks could complicate performance in a higher-rate environment.
A new analysis by Investing.com has identified five U.S. banking stocks with market capitalizations over $1 billion that show the highest modeled valuation upside. Atlanticus Holdings (ATLCP) and Inter & Co (INTR) lead the list, though the report highlights specific risks associated with each institution that could temper performance.
Key Findings from the Analysis
According to the September 15 report, the screen identified the following banks based on their potential fair value upside, while noting that this is not a guarantee of performance:
- Atlanticus Holdings (ATLCP): 47.6% modeled upside. The analysis points to its strong Return on Equity (ROE) of 22.9% but cautions about its higher sensitivity to credit quality.
- Inter & Co (INTR): 44.2% modeled upside. Analysts project an even greater upside of 60.0%, though the firm carries risks related to interest rates and emerging markets.
- Central Bancompany (CBC): 42.8% modeled upside. A significant gap exists with its analyst consensus target upside of just 7.6%.
- Renasant (RNST): 38.1% modeled upside, described as a more conventional regional bank exposure.
- Walker & Dunlop (WD): 37.4% modeled upside. Its outlook is complicated by significant exposure to the mortgage and commercial real estate (CRE) sectors.
How Interest Rates Impact Bank Profitability
For many banks, rising interest rates can be beneficial in the short term by expanding the net interest margin (NIM)—the difference between income from loans and the cost of funding. This occurs because floating-rate loans and new lending can reprice higher more quickly than customer deposit rates.
AdHowever, the source material explains that this benefit is not guaranteed and can be offset by several factors. These include intensified competition for deposits, which drives up funding costs, and the immediate repricing of wholesale funding sources. Additionally, a bank's existing portfolio of fixed-rate bonds can lose market value in a rising-rate environment.
Balancing Valuation with Balance Sheet Risks
The Investing.com report stresses that the list should be viewed as a valuation watchlist rather than a direct trade recommendation for a rate-hike scenario. The ultimate impact of monetary policy depends heavily on the specific structure of each bank's balance sheet.
The analysis suggests that the most favorably positioned lenders would be those with a high concentration of floating-rate assets, a stable base of low-cost retail deposits, and limited exposure to sectors sensitive to economic downturns, such as commercial real estate.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.

Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.

Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.

Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.